← All trials
NCT04622319
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Sep 1, 2027
- First posted
- Nov 9, 2020
- Last posted
- Nov 9, 2020
- Enrollment
- 1600
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daiichi SankyoLead sponsor
- NSABP FoundationCollaborator
- AstraZenecaCollaborator
- Daiichi SankyoStudy director
- German Breast Group Forschungs GmbHCollaborator
- Spanish Breast Cancer Research GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.